Evidence map›Paper›PMID 33767863›Full record

ArticleMolecular and clinical oncology2021

IP6K2 predicts favorable clinical outcome of primary breast cancer.

Josefine Sandström, Alien Balian, Rebecca Lockowandt, Tommy Fornander, Bo Nordenskjöld, Linda Lindström, Gizeh Pérez-Tenorio, Olle Stål

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Targeting IPNature communications · 2026
    Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Josefine SandströmDepartment of Biomedical and Clinical Sciences and Department of Oncology, Linköping University, 581 83 Linköping, Sweden.
Alien BalianDepartment of Biomedical and Clinical Sciences and Department of Oncology, Linköping University, 581 83 Linköping, Sweden.
Rebecca LockowandtDepartment of Biomedical and Clinical Sciences and Department of Oncology, Linköping University, 581 83 Linköping, Sweden.
Tommy FornanderDepartment of Oncology-Pathology, Karolinska Institute, 171 76 Stockholm, Sweden.
Bo NordenskjöldDepartment of Biomedical and Clinical Sciences and Department of Oncology, Linköping University, 581 83 Linköping, Sweden.
Linda LindströmDepartment of Biosciences and Nutrition, Karolinska Institute, 141 83 Stockholm, Sweden.
Gizeh Pérez-TenorioDepartment of Biomedical and Clinical Sciences and Department of Oncology, Linköping University, 581 83 Linköping, Sweden.
Olle StålDepartment of Biomedical and Clinical Sciences and Department of Oncology, Linköping University, 581 83 Linköping, Sweden.
Linköping University · SEKarolinska Institutet · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The inositol hexakisphosphate kinase (

Indexed as

3p21.31Aktinositol hexakisphosphate kinase 1PI3K/Akt/mTOR pathwayprognosisTP53

Identifiers

PMID33767863
PMCPMC7976380
OpenAlexW3138398582

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.